LPL Financial
EVFM

LPL Financial’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

LPL Financial’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,750
Closed -$9K – 4582
2022
Q1 		$9K Buy
+1,750
New +$11K ﹤0.01% 4156

Other funds holding EVFM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial's EVFM Position: Q2 2022 in Review

LPL Financial sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,750 shares — an estimated $9K sold.

LPL Financial first reported a position in EVFM in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • LPL Financial reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • LPL Financial sold 1,750 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $9K.
  • LPL Financial first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • LPL Financial's Evofem Biosciences, Inc. Common Stock position peaked at $9K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on LPL Financial's 13F filing for Q2 2022, filed 12 Aug 2022.